RSS

Japan Atherosclerosis Society (JAS)

France's Sanofi and US partner Regeneron Pharmaceuticals have reported that the phase 3 trial of drug Praluent reduced cholesterol in 69% of Japanese patients in a phase 3 trial. more

News